Pieter Vynckier1, Giulia Ferrannini2, Lars Rydén2, Lale Tokgözoğlu3, Jan Bruthans4, Kornelia Kotseva5,6, David Wood5,6, Tine De Backer7, Sofie Gevaert7, Dirk De Bacquer8, Delphine De Smedt8. 1. Department of Public Health and Primary Care, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium. Pieter.Vynckier@Ugent.be. 2. Cardiology Unit, Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden. 3. Department of Cardiology, Hacettepe University, Ankara, Turkey. 4. Centre for Cardiovascular Prevention, First Faculty of Medicine and Thomayer Hospital, Charles University, Prague, Czech Republic. 5. National Institute for Prevention and Cardiovascular Health, National University of Ireland, Galway, Ireland. 6. National Heart & Lung Institute Imperial College London, London, UK. 7. Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium. 8. Department of Public Health and Primary Care, Ghent University, Corneel Heymanslaan 10, 9000, Ghent, Belgium.
Abstract
PURPOSE: This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). METHODS: Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (≥ 6 months to < 2 years after hospitalization) was collected. RESULTS: Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%; P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%; P < 0.001) and calcium channel blockers (21.2% vs. 28.8%; P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%; P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%; P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. CONCLUSION: The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.
PURPOSE: This study is aimed at investigating gender differences in the medical management of patients with coronary heart disease (CHD). METHODS: Analyses were based on the ESC EORP EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) survey. Consecutive patients between 18 and 80 years, hospitalized for a coronary event, were included in the study. Information on cardiovascular medication intake at hospital discharge and at follow-up (≥ 6 months to < 2 years after hospitalization) was collected. RESULTS: Data was available for 8261 patients (25.8% women). Overall, no gender differences were observed in the prescription and use of cardioprotective medication like aspirin, beta-blockers, and ACE-I/ARBs (P > 0.01) at discharge and follow-up respectively. However, a statistically significant difference was found in the use of statins at follow-up, in disfavor of women (82.8% vs. 77.7%; P < 0.001). In contrast, at follow-up, women were more likely to use diuretics (31.5% vs. 39.5%; P < 0.001) and calcium channel blockers (21.2% vs. 28.8%; P < 0.001), whereas men were more likely to use anticoagulants (8.8% vs. 7.0%; P < 0.001). Overall, no gender differences were found in total daily dose intake (P > 0.01). Furthermore, women were less likely than men to have received a CABG (20.4% vs. 13.2%; P < 0.001) or PCI (82.1% vs. 74.9%; P < 0.001) at follow-up. No gender differences were observed in prescribed (P = 0.10) and attended (P = 0.63) cardiac rehabilitation programs. CONCLUSION: The EUROASPIRE V results show only limited gender differences in the medical management of CHD patients. Current findings suggest growing awareness about risk in female CHD patients.
Entities:
Keywords:
Cardiovascular diseases; EUROASPIRE; Gender; Medical treatment
Authors: Ioannis T Farmakis; Stefanos Zafeiropoulos; Ioannis Doundoulakis; Andreas S Papazoglou; Efstratios Karagiannidis; George Giannakoulas Journal: Am J Prev Cardiol Date: 2022-04-04
Authors: Murat Cimci; Jawed Polad; Mamas Mamas; Andres Iniguez-Romo; Bernard Chevalier; Rajpal Abhaichand; Adel Aminian; Ariel Roguin; Gabriel Maluenda; Michael Angioi; Graham Cassel; Shoichi Kuramitsu; Lotte Jacobs; Roxane Debrus; Fazila Malik; David Hildick-Smith; Peep Laanmets; Marco Roffi Journal: Heart Date: 2022-07-27 Impact factor: 7.365